au Udvalget for Humanmedicinske Lægemidler (CHMP) besluttede, at fordelene ved Monotard er større end risiciene ved behandling af diabetes.
The Committee for Medicinal products for Human Use (CHMP) decided that Monotard’ s benefits are greater than its risks for the treatment of diabetes.